Literature DB >> 31702083

Interleukin-27 is abrogated in gastric cancer, but highly expressed in other Helicobacter pylori-associated gastroduodenal diseases.

Gifone A Rocha1, Fabrício F de Melo2, Mônica M D A Cabral3, Breno B de Brito2, Filipe A F da Silva2, Dulciene M M Queiroz1.   

Abstract

BACKGROUND: IL-27 has dual roles in the immune response either stimulating Th1 or inhibiting Th17 cells. Because there is a particular link of IL-23/Th17 axis in the development of cancer and IL-27 has been considered a potential treatment for cancer, we evaluated the gastric and serum concentrations of IL-27 in two mutually exclusive Helicobacter pylori-associated diseases, gastric cancer (GC) and duodenal ulcer (DU).
MATERIAL AND METHODS: We prospectively studied 110 H pylori-positive patients and 40 healthy blood donors. Serum and gastric concentrations of IL-27 and cytokines of the Th1/Th17 cells were assessed by ELISA.
RESULTS: IL-27 was not detected in GC patients, but the cytokine concentration was very high in the patients with DU. IL-27 was also detected in the gastritis patients and in the H pylori-positive blood donors. IL27RA mRNA expression in peripheral blood mononuclear cells, evaluated by rt-PCR, was stimulated by H pylori strains. The cytokine concentration positively correlated with the Th1 and negatively with Th17 cell representative cytokine levels. Gastric IL-27 concentrations were positively correlated with increased degree of mononuclear and polymorphonuclear cells on the antral gastric mucosa of DU patients in consonance with the DU gastritis pattern. IL-12p70 and IFN-γ gastric concentrations were significantly higher in DU than in GC. Conversely, gastric concentrations of Th17 cell-associated cytokines (IL-1β, IL-6, IL-17A, IL-23, and TGF-β) were significantly higher in GC than in DU patients.
CONCLUSION: Although H pylori infection is able to elicit IL-27 and IL-27Rα secretion, DU and GC have diametrically opposed cytokine patterns.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990Helicobacter pylorizzm321990; IL-27; Th1; Th17 cytokines; duodenal ulcer; gastric cancer

Mesh:

Substances:

Year:  2019        PMID: 31702083     DOI: 10.1111/hel.12667

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  5 in total

1.  Characterization of Gastric Tissue-Resident T Cells in Autoimmune and Helicobacter pylori-Associated Gastritis.

Authors:  Daisuke Kametaka; Masaya Iwamuro; Takahide Takahashi; Araki Hirabata; Kenta Hamada; Yoshiyasu Kono; Hiromitsu Kanzaki; Seiji Kawano; Takehiro Tanaka; Fumio Otsuka; Yoshiro Kawahara; Hiroyuki Okada
Journal:  Curr Issues Mol Biol       Date:  2022-05-25       Impact factor: 2.976

2.  Helicobacter pylori infection: How does age influence the inflammatory pattern?

Authors:  Glauber Rocha Lima Araújo; Hanna Santos Marques; Maria Luísa Cordeiro Santos; Filipe Antônio França da Silva; Breno Bittencourt da Brito; Gabriel Lima Correa Santos; Fabrício Freire de Melo
Journal:  World J Gastroenterol       Date:  2022-01-28       Impact factor: 5.742

Review 3.  From Helicobacter pylori infection to gastric cancer: Current evidence on the immune response.

Authors:  Vinícius Lima de Souza Gonçalves; Maria Luísa Cordeiro Santos; Marcel Silva Luz; Hanna Santos Marques; Breno Bittencourt de Brito; Filipe Antônio França da Silva; Cláudio Lima Souza; Márcio Vasconcelos Oliveira; Fabrício Freire de Melo
Journal:  World J Clin Oncol       Date:  2022-03-24

4.  Interleukin 27 Protects From Gastric Atrophy and Metaplasia During Chronic Autoimmune Gastritis.

Authors:  Kevin A Bockerstett; Christine P Petersen; Christine N Noto; Lindsey M Kuehm; Chun Fung Wong; Eric L Ford; Ryan M Teague; Jason C Mills; James R Goldenring; Richard J DiPaolo
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2020-05-04

Review 5.  Immunological Aspects of the Tumor Microenvironment and Epithelial-Mesenchymal Transition in Gastric Carcinogenesis.

Authors:  Jacek Baj; Karolina Brzozowska; Alicja Forma; Amr Maani; Elżbieta Sitarz; Piero Portincasa
Journal:  Int J Mol Sci       Date:  2020-04-06       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.